Syntara Returns After A$10m Raise and FDA Win
Syntara (ASX:SNT) resumed trading yesterday with two pieces of good news in the same week: A$10 million in fresh capital and a thumbs-up from the US FDA on its next big trial for amsulostat (formerly SNT-5505), the company’s lead drug. Shares slipped 12.5% to A$0.028, suggesting some investors took profits or were unhappy with the dilution. But the order of events tells a more positive story than the share price reaction. The FDA approval came first, and the funding followed. This wasn’t a rescue raise; it was well-timed funding that now carries Syntara through every major milestone for the next 18 months.
What are the Best ASX Stocks to invest in right now?
Syntara Clears a Major Hurdle With FDA Backing for Its Lead Drug
The FDA gave the green light to the design of Syntara’s Phase 2b trial for amsulostat, a treatment for myelofibrosis, a rare and serious bone marrow cancer. The trial will focus on patients who don’t respond well to current treatments, a group with very few options today.
Some context matters here. Back in 2025, the FDA asked Syntara to run an additional Phase 2b study before moving to Phase 3, which added cost and time to the program. This week’s news is the FDA approving the design of that study, so Syntara has now cleared the bar that the regulator set. The trial design and pathway are agreed upon, removing a major source of uncertainty and opening the door for serious conversations with bigger pharmaceutical companies. Combined with the Fast Track status amsulostat already holds, Syntara now has the clearest regulatory path it’s ever had.
A$10m Raise Funds a Busy 2026 Without Returning to the Market
The raise was split into A$8m from institutions and A$2m for retail investors through a share purchase plan, both priced at A$0.027 per share, a 15.6% discount to the last close before the halt. Combined with the A$12.3m Syntara held at the end of last quarter, the company is now sitting on around A$22m, enough cash to last until the third quarter of 2027.
What this buys is what really matters. Syntara has five trial results coming across in 2026, including Phase 2 data on SNT-4728 for a Parkinson’s-related sleep disorder, results from the SNT-9465 hypertrophic scarring study, and ongoing updates on amsulostat in myelofibrosis and myelodysplastic syndrome. We believe the real value of this raise isn’t the dollar amount, but that Syntara won’t need to come back to investors before any of these milestones. If the data lands well, the next conversation is with a partner, not with shareholders.
The Investor’s Takeaway for SNT
At roughly A$50m market cap, Syntara is still a speculative small-cap. But the setup here is unusually clean for biotech: an FDA-backed Phase 2b plan, Fast Track status, fully funded catalysts, and a credible comparable in Cytopia’s myelofibrosis drug, momelotinib, which GSK eventually acquired via Sierra Oncology for US$1.9 billion in 2022, the largest deal ever for an Australian-invented drug.
The risks are real. Phase 2b approval isn’t commercial approval, partnership talks can stall, and most early-stage biotechs don’t make it to market. Yesterday’s 12.5% drop is a reminder that even good news can trigger short-term selling. In our view, risk-tolerant investors get genuine asymmetric upside from the busy 2026 catalyst calendar. More cautious investors may prefer to wait for the SNT-4728 Parkinson’s data before getting involved.
